Communiqués de presse AbbVie Santé & sciences de la vie — Flux RSS et veille en direct
PPN World suit le flux RSS de AbbVie en temps réel — 5 communiqués indexés au cours des 30 derniers jours, le plus récent est arrivé il y a 4 h. Suivez-le avec alertes sur recherches enregistrées, résumés IA et recherche plein texte, ou branchez l'URL RSS ci-dessous dans votre propre lecteur.
URL du flux RSS de AbbVie
https://news.abbvie.com/index.php?s=2429&pagetemplate=rssÀ propos de ce fil
AbbVie fait partie des 1200+ fils de presse que PPN World surveille en continu — un fil en anglais axé sur le secteur Santé & sciences de la vie, classé sous « États-Unis » dans notre index par pays. Chaque communiqué est dédupliqué, géolocalisé et enrichi d'un résumé IA, et vous pouvez y attacher des alertes sur recherches enregistrées. AbbVie est un fil spécialisé à faible volume — 5 communiqués dans les 30 derniers jours : le genre de source qui mérite une alerte plutôt qu'un défilement.
Comment suivre les communiqués de AbbVie
- Copiez l'URL du flux RSS de AbbVie affichée ci-dessus.
- Collez-la dans n'importe quel lecteur RSS (Feedly, Inoreader, NetNewsWire…) pour recevoir le flux brut.
- Ou suivez AbbVie dans PPN World pour ajouter déduplication, alertes sur recherches enregistrées et résumés IA sur les 1200+ fils.
Derniers communiqués de AbbVie
- JUVÉDERM® Day Returns to U.S. on August 19il y a 4 h
Allergan Aesthetics celebrates fourth annual JUVÉDERM ® Day with buy-one-get-one (BOGO) gift cards and double points for Allē Members This summer marks the 20th anniversary of the brand's first...
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areatail y a 1 j
RINVOQ® is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA) Approval was based on the pivotal Phase 3 UP-AA clinical program, whic…
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligoil y a 1 j
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phas…
- Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)il y a 6 j
COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026 Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE® DLBCL-1 trial and was not met...
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patientsil y a 13 j
Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹...
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Developmentil y a 16 j
SkinMedica® launches Regenerative Science Advisory Board to shape future innovation Expands its state-of-the-art research and development (R&D) facility to support the next generation of...
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphomail y a 23 j
TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of relapsed or refractory follicular lymphoma in...
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphomail y a 30 j
Topline results from Phase 3 EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in...
- AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areatail y a 31 j
Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score ≤ 20 and key...
Les plus récents communiqués de ce fil défilent en direct pour les membres PPN World.